Hawaii 2026 Regular Session

Hawaii House Bill HB2456

Introduced
1/28/26  
Refer
2/2/26  
Report Pass
2/18/26  

Caption

Relating To Drugs For Weight Loss.

Impact

If enacted, this bill would potentially change the landscape of drug coverage under Medicaid for weight-loss treatments in Hawaii. By allowing coverage for GLP-1 drugs such as Saxenda and Wegovy, the state would be acknowledging their effectiveness not only in treating obesity but also in reducing associated healthcare costs in the long term. The bill stipulates that coverage must include specific conditions, such as prior participation in a lifestyle change program, which emphasizes comprehensive healthcare strategies rather than solely relying on medication.

Summary

House Bill 2456 aims to require the Department of Human Services in Hawaii to provide Medicaid coverage for glucagon-like peptide-1 (GLP-1) drugs, which are FDA-approved for weight loss. This legislative change is driven by the recognition of the increasing public health issue of obesity and its related health complications, such as diabetes and heart disease. The bill seeks to address the exclusion of these medications from typical Medicaid coverage, thereby improving access for those who need these drugs for weight management.

Sentiment

The general sentiment regarding HB 2456 appears to be supportive among healthcare advocates and those impacted by obesity. Supporters argue that this legislation is essential for public health, as it addresses a significant barrier to effective treatment for obesity. However, there might be concerns regarding costs and the implications on the state's Medicaid budget, suggesting a divide in opinions among legislators and stakeholders about fiscal responsibility versus health outcomes.

Contention

A notable point of contention surrounding the bill is its financial implications for the state Medicaid program. Critics may argue that expanding Medicaid coverage can strain resources, while proponents insist on the potential long-term cost savings associated with better health outcomes from effective obesity treatment. The required lifestyle change program alongside medication would spark discussions on the adequacy and practicality of state support for comprehensive weight management strategies.

Companion Bills

HI SB3195

Same As Relating To Drugs For Weight Loss.

Previously Filed As

HI SB1509

Relating To Prescription Drugs.

HI HB951

Relating To Prescription Drugs.

HI HB386

Relating To Dangerous Drugs.

HI SB1245

Relating To Pharmacists.

HI HB216

Relating To Prescription Drugs.

HI HB553

Relating To Insurance.

HI SB279

Relating To Dangerous Drugs.

HI HB820

Relating To Health Insurance.

HI HB705

Relating To The Executive Office On Aging.

HI SB850

Relating To Disability Health Disparity.

Similar Bills

No similar bills found.